NEW YORK, March 28, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased LPL Financial Holdings Inc. (NASDAQ:LPLA) securities between December 8, 2015 and February 11, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/lpl-financial-holdings-inc. There is no cost or obligation to you.
The complaint alleges that during the Class Period, defendants issued false and misleading statements and/or failed to disclose adverse information regarding LPL’s business and prospects, including that: (a) LPL’s earnings and revenue were not steady, but were substantially declining; (b) LPL’s client assets were not in the midst of a recovery, but were actually deteriorating and would decline by billions of dollars; (c) LPL’s gross profits would not decline “slightly”, as indicated, but significantly, (d) LPL would in fact experience its worst sequential gross profit decline in four years; and (e) as a result of the aforementioned, LPL common stock would trade at artificially inflated prices during the Class Period.
If you suffered a loss in LPL Financial Holdings you have until May 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/lpl-financial-holdings-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 



